Budesonide (BUD) plus formoterol (FORM) for both maintenance and symptom relief (BUDFORM for all) v fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA) in asthma*
Outcome at 1 year | Comparisons | Event rates | RRR (95% CI) | NNT (CI) |
---|---|---|---|---|
*Abbreviations defined in glossary; RRR, NNT, and CI calculated from Cox proportional hazard ratios in article. | ||||
⩾1 severe asthma exacerbation | BUDFORM for all v BUDFORM plus SABA | 16% v 27% | 41% (30 to 52) | 10 (8 to 13) |
BUDFORM for all v BUD plus SABA | 16% v 28% | 43% (31 to 53) | 9 (7 to 12) |